MedTrace Logo

Lipid Lowering Therapy After Cardiac Rehabilitation LLT-R-Registry

NCT02749279 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1100

Last updated 2019-08-28

No results posted yet for this study

Summary

The most important drugs for evidence based lipid lowering treatment (LLT) in CHD are statins. All patients with established CHD should be treated with statins irrespective of low density lipoprotein (LDL) cholesterol (LDL-C) levels. The goals of treatment are LDL-C below 1.8 mmol/L (70 mg/dL) or 50% LDL-C reduction when target level cannot be reached. Unfortunately, several patients cannot achieve treatment targets also related to the serious problem of adherence to therapy, which includes also LLT.

Conditions

  • Lipid Lowering Therapy After Cardiac Rehabilitation

Sponsors & Collaborators

  • KKS Netzwerk

    collaborator NETWORK

  • Paracelsus Harz Clinic Bad Suderode.

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-06-30
Completion
2020-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749279 on ClinicalTrials.gov